Opinion

Video

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      John Taylor, III, MD, on novel options in NMIBC
      John Taylor, III, MD, on novel options in NMIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      What a long-term study of patients undergoing RARC reveals about upstaging
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
      Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
      Neeraja Tillu, MD, answers a question during a Zoom video interview
      Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC
      Investigators highlight real-world data on nadofaragene firadenovec in NMIBC
      Investigators highlight real-world data on nadofaragene firadenovec in NMIBC
      Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC
      Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC
      Related Content
      RAG-01 elicits complete responses in NMIBC
      March 26th 2025

      RAG-01 elicits complete responses in NMIBC

      Hannah Clarke
      "The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Bel-sar shows promising safety, efficacy in NMIBC
      March 26th 2025

      Bel-sar shows promising safety, efficacy in NMIBC

      Hannah Clarke
      In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC
      March 24th 2025

      Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC

      Hannah Clarke
      “The addition of the durvalumab did not make treatment more morbid than chemotherapy alone, and it didn't change or increase the surgical complications you saw in the ward," says James W.F. Catto, MBChB, PhD, FRCS.
      Nadofaragene firadenovec maintains safety, efficacy in real-world population
      March 20th 2025

      Nadofaragene firadenovec maintains safety, efficacy in real-world population

      Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke
      "The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
      © 2025 MJH Life Sciences

      All rights reserved.